WO2005058064A1 - アスタキサンチン配合ペット用食物 - Google Patents
アスタキサンチン配合ペット用食物 Download PDFInfo
- Publication number
- WO2005058064A1 WO2005058064A1 PCT/JP2004/018950 JP2004018950W WO2005058064A1 WO 2005058064 A1 WO2005058064 A1 WO 2005058064A1 JP 2004018950 W JP2004018950 W JP 2004018950W WO 2005058064 A1 WO2005058064 A1 WO 2005058064A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- astaxanthin
- pet
- acid
- pet food
- food
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention has an effect of deodorizing excrement such as urine and feces, an effect of improving sleep, an effect of improving sensitivity such as perception and cognitive ability, an effect of improving vision, and a treatment, improvement, and prevention effect of diabetes and diabetic complications.
- Pet foods such as mice, rats, guinea pigs, egrets, monkeys, dogs, cats, hamsters, pigs, cows, sheep, horses, penguins, snakes, lizards and birds containing astaxanthin and Z or its esters Things.
- Astaxanthin is a kind of carotenoid same as i3_carotenoid, and it is a crustacean such as shrimp and riki, fish such as salmon and Thailand, algae such as matococcus green alga, and yeasts such as red yeast fafia. It is a red pigment with a rich dietary experience that is widely distributed in nature, especially in the ocean.
- astaxanthin has a potent antioxidant action 100-100,000 times that of vitamin ⁇ ( ⁇ -tocopherol) and about 40 times that of ⁇ -toxin. Astaxanthin has been expected from the industry as a health food since the time of treatment.
- Other functional properties of astaxanthin include anti-inflammatory, anti-atherosclerotic, anti-diabetic, protective retinal effects against light damage, circadian rhythm regulation, immunostimulation, anti-stress, and muscle retention Numerous reports have been made on the effects of improving sperm quality and suppressing bladder cancer induction. In addition, as effects on skin, effects of inhibiting pigmentation, inhibiting melanin production, and inhibiting photoaging have been reported.
- astaxanthin and / or its ester power Deodorant effect of excretion of urine and feces of pet, sleep improvement effect, sensitivity improvement effect such as perception and cognitive ability, visual improvement effect, treatment of diabetes and diabetic complications ⁇ Improvement ⁇ It is known to have a preventive effect.
- Pet foods having a sleep improving effect include a composition comprising tributophan and a carbohydrate for promoting onset of sleep in animals (see Patent Document 5), and a mammal containing a novel melatonin derivative as an active ingredient. And a pharmaceutical composition for treating an age-related behavioral disorder of a pet animal containing an acetylcholinesterase 'inhibitor (see Patent Document 7).
- Patent Document 7 also describes administration of an acetylcholinesterase ′ inhibitor that improves the sensitivity of pets.
- Patent Document 2 Japanese Patent Application Laid-Open No. 3-266943
- Patent Document 3 Japanese Patent Application Laid-Open No. 2001-258480
- Patent Document 4 JP-A-2002-114690
- Patent Document 5 JP-A-58-201715
- Patent Document 6 JP-A-7-196493
- Patent Document 7 JP-A-2000-309545
- Patent Document 8 U.S. Pat.No. 5,527,533
- Patent Document 9 International Publication No. 02/094253 pamphlet
- Patent Document 10 JP-A-10-276721
- the present invention provides a mouse having a deodorizing effect of excrement such as feces and urine of a pet, a sleep improving effect, a sensitivity improving effect, a visual improving effect, a treatment, an improvement and a prevention effect of diabetes and diabetic complications.
- the purpose of the present invention is to provide food for pets such as horses, rats, guinea pigs, egrets, monkeys, dogs, cats, wild cats, mustards, pigs, cows, sheep, horses, horses, snakes, lizards and birds.
- the inventors conducted research on the above points, and as a result, it was found that astaxanthin and / or its ester deodorize the excrement of feces and urine of pets, improve sleep, improve sensitivity, and improve vision.
- the present invention was found to have an effect, a treatment, an improvement and a prevention effect for diabetes and diabetic complications, and completed the present invention.
- the present invention has been made based on such findings.
- Pet food characterized by containing astaxanthin and Z or its ester
- Pet food according to (1) which has a sleep improving effect comprising astaxanthin and Z or an ester thereof.
- Pet food according to (1) which has a visual improvement effect comprising astaxanthin and / or an ester thereof.
- the pet is at least one of a mouse, a rat, a guinea pig, a heron, a monkey, a dog, a cat, a hamster, a pig, a cow, a sheep, a horse, a penis, a snake, a lizard, and a bird ( 1) One (6) food for pets and
- the odor of the excrement of the pet is reduced, the sensitivity of the pet is improved, and the reaction to humans is improved. Is more noticeable and the pet sleeps better to improve health, improve vision, It can treat, improve, and prevent diabetic complications, and can better keep pets.
- astaxanthin means a product derived from a natural product or obtained by synthesis.
- Natural products include, for example, crustaceans such as shrimp, krill and riki, shells and eggs and organs of various species, skins and eggs of various seafood, algae such as green alga Hematococcus, and yeasts such as red yeast Phaffia. And those obtained from seed plants such as marine bacteria, eubacterium, fukusou and kinbori. Extracts and synthetic compounds from nature are commercially available and readily available.
- Astaxanthin can be obtained, for example, by culturing red yeast puffer, green alga Hematococcus, marine bacteria and the like in an appropriate medium according to a known method.
- Matococcus is most suitable for green algae because of its low cultivation and extraction, the highest concentration of astaxanthin, and high productivity.
- a culture method for obtaining a green algae having a high astaxanthin content of matococci a closed culture method in which foreign microorganisms are mixed and the propagation of other contaminants is small is preferred, for example, a closed dome.
- a method for culturing using a culture medium having a shape, a conical or cylindrical culture device and a gas discharge device movable in the device (see WO 99/50384), or a closed culture device
- the method of culturing by irradiating light from the inside with a light source and the method of culturing in a plate-shaped culture tank are suitable.
- astaxanthin is contained in an oil-soluble organic solvent such as acetone, alcohol, ethyl acetate, benzene, and chloroform from natural products containing astaxanthin.
- the components can be extracted. After the extraction, the solvent is removed according to a conventional method to obtain a mixed concentrate of monoestenol-type astaxanthin and diester-type astaxanthin. The concentrate obtained may be further purified if desired.
- Astaxanthin can be used in the form of extract of astaxanthin obtained by the above method and a powder or an aqueous solution containing the same, or a dried product such as red yeast fafia, green alga matococcus and marine bacteria. Those crushed products can be used.
- Astaxanthin is 3,3'-dihydroxy-, one carotene-1,4 dione and has a stereoisomer. Specifically, three stereoisomers of (3R, 3'R) -astaxanthin, (3R, 3'S) -astaxanthin and (3S, 3'S) -astaxanthin are known. Either of these forces can be used in the present invention.
- astaxanthin includes astaxanthin and / or an ester thereof. Further, esters of astaxanthin include monoester and / or diester forms.
- Astaxanthin is known to be a highly safe compound with no mutagenicity observed.
- the pet food containing astaxanthin of the present invention as an active ingredient at least one of a free form, a monoester form, and a diester form of astaxanthin can be used. Since the ester form has two hydroxyl groups protected by an ester bond, it is physically more stable than the free form and the monoester form and is less susceptible to oxidative degradation in pet food. However, it is considered that when taken into a living body, it is rapidly hydrolyzed to astaxanthin by an in-vivo enzyme, and shows an effect.
- Examples of the monoester of astaxanthin include lower or higher saturated fatty acids or esters esterified by lower or higher unsaturated fatty acids.
- Specific examples of the lower or higher saturated fatty acids or lower or higher unsaturated fatty acids include acetic acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitooleic acid, heptadecanoic acid, elaidic acid, ricinoleic acid, betroceric acid, Batacenoic acid, Eleostearic acid, Punicic acid, Licanic acid, Parinaric acid, Gadoric acid, 5-Eicosenoic acid, 5-Docosenoic acid, Cetolic acid, Erucic acid, 5,13-Docosagenic acid, Seracholic acid, Decenoic acid, Examples include steric acid, dodecenoic acid, oleic acid, stearic acid, eicosapentaenoic acid, docosa
- amino acids such as glycine and alanine
- Monovalent or polyvalent carboxylic acids such as acetic acid and citric acid
- inorganic acids such as phosphoric acid and sulfuric acid
- sugars such as darcoside
- sugar fatty acids such as glycemic sugar fatty acid and sphingosaccharide fatty acid
- fatty acids such as glycemic fatty acid
- Monoesters esterified with glyceric phosphoric acid or the like can be given.
- salts of the monoesters are also included.
- Astaxanthin diesters include the lower saturated fatty acids, higher saturated fatty acids, lower unsaturated fatty acids, higher unsaturated fatty acids, amino acids, mono- or polycarboxylic acids, inorganic acids, sugars, sugar fatty acids, fatty acids And diesters esterified with the same or different acids selected from the group consisting of glycerol and phosphoric acid.
- the salts of the diesters are also included.
- Examples of the diester of glycerol phosphoric acid include saturated fatty acid esters of glyceric phosphoric acid and glycerol phosphates containing fatty acids selected from higher unsaturated fatty acids, unsaturated fatty acids and saturated fatty acids. And so on.
- antioxidants include, for example, vitamin Es (tocopherols), vitamin Cs, carotenoids, polyphenols, oils containing unsaturated fatty acids, and other natural extracts.
- Vitamin Es include vitamin E, tocotrile and derivatives thereof. It is good to use an oil containing at least one of them as vitamin Es.
- Specific examples of vitamin Es include dl ⁇ -tocopherol, d ⁇ -tocopherol, dl ⁇ -tocopherol acetate, d- ⁇ -tocopherol acetate, dl_ct-tocopherol succinate, d- ⁇ -tocopherol succinate Nore, nicotinic acid dl- ⁇ -tocopherolone, nicotinic acid d- ⁇ -tocopherolone, d // 3-tocopherol, d-j3-tocopherol, dl- / 3-tocopherol acetate, d_ ⁇ -tocopherol acetate, succinic acid dl_ ⁇ -tocopherol, succinic acid d_ ⁇ -tocopherol, nicotinic acid tocopherol, nicotinic acid d_i3-to
- tocopherol d_ [delta] - tocopherol, acetic DL_ .delta. tocopherol acetate d_ .delta. tocopherols, succinic acid dl - ⁇ -tocopherol, succinic acid d_ ⁇ -tocopherol, nicotinic acid dl- ⁇ -tocopherol nore, nicotinic acid d_ ⁇ -tocopherol, ⁇ -tocotrienole, monotocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol And the like.
- dl- ⁇ -tocopherol acetic acid dl-one-tocopherol, succinic acid dl-one-tocopherol, nicotinic acid dl-one-tocopheronele, one-tocotrienole, / 3-tocotrienole, ⁇ - Tocotrienol is preferred.
- Vitamin Cs include vitamin C and its derivatives.
- Vitamin C derivatives include, for example, glycosides such as ascorbic acid darcoside, L-asconorevir palmitate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, and L-ascorbyl diisopalmitate.
- carotenoids examples include ⁇ -carotene, ⁇ -carotene, lycopene, rutin, canthaxanthin, astaxanthin, zeaxanthin, one apo-1 8'-carotene derived from Rikuguchi tinnerore and donariella, carrot, palm oil, And tomato pigments.
- Unsaturated fatty acid-containing oils include unsaturated fatty acids such as linoleic acid, arachidonic acid, polylinolenic acid, eicopentaenoic acid, and docosahexanoic acid, dali celloids containing these unsaturated fatty acids, and unsaturated fatty acids of these unsaturated fatty acids.
- Oils containing phospholipids such as sesame oil, sesame oil, kiwi seed oil, camellia oil, barley oil, grape seed oil, black plant oil, borage seed oil, evening primrose oil, large Hemp oil, corn oil, soybean oil, linseed oil, butter, lard, coconut oil, coconut oil, olive oil, canola oil, fresh safflower, fish oil and the like.
- Other natural extracts include escozuki kogi extract, kiwi extract, Clara extract, cake extract, Hongjing heaven extract, coffee extract, wheat extract, saishin extract, peony extract, Sempukuka extract, Tsukimiso extract, tomato extract, grape extract, black power plant extract, spinach power extract, merosuria extract, okuinin extract, artea extract, Ibukitorano extract, nettle extract, and chinko extract Extract, oak extract, oak extract, seaweed extract, gentian extract, Scutellaria extract, confectionery extract, perilla extract, honeysuckle extract, cinnamon extract, bean tea extract, corn extract, saxifrage Extract, rosemary extract, Remoko extract, foliage extract, blueberry extract, etc. It is.
- the ratio of astaxanthin to the above-mentioned antioxidant varies depending on the type of astaxanthin / antioxidant to be blended, but is usually 1 part by weight of astaxanthin.
- the antioxidant is 0.1 to 200 parts by weight, preferably 0.2 to 20 parts by weight, preferably 1 part by weight of astaxanthin.
- the antioxidant is antioxidant to 1 part by weight of astaxanthin.
- the agent is 0.5-5 parts by weight.
- the pet food of the present invention containing astaxanthin has an effect of deodorizing pet excrement, improving sleep, improving sensitivity, improving vision, and treating, improving and preventing diabetic and diabetic complications. Can be used for purpose.
- the excrement deodorizing effect in the present invention refers to deodorization, deodorization and deodorization of pet excrement, and by providing pet food containing astaxanthin, the malodor of pet manure is significantly reduced. It is to be reduced to. Astaxanthin inhibits intestinal bacteria and plant-derived proteases that decompose urea, which generates ammonia, which is the main cause of foul odors, and promotes the growth of useful intestinal bacteria by improving the intestinal environment. It is considered that there is.
- the sleep improving effect of the pet in the present invention is an effect of improving, treating, and suppressing sleep disorders caused by stress, illness, changes in life rhythm, taking drugs, physical illness, aging, and the like.
- Sleep disorder refers to insomnia such as difficulty falling asleep and difficulty falling asleep. Difficulty in sleep is that the person wakes up many times in the night and sleeps shallowly, wakes up midnight, wakes up near dawn and cannot sleep until morning, ⁇ early awakening '', Symptoms such as difficulty in feeling sleep I can get lost.
- the effect of improving the sensibility of a pet in the present invention means that impairment of perception or cognitive ability caused by stress, illness, changes in living rhythm, aging, etc. is improved, treated, or suppressed. For example, respond sensitively to sounds or strangers, or be happy when the owner acts or feeds the pet to get the pet's attention. And the tendency of pets to draw attention to their owners, and to increase the likelihood of giving appropriate greetings to their owners. Improving the physical condition has the effect of improving the fur, etc.
- the visual improvement effect of a pet in the present invention means that visual impairment caused by stress, illness, change in life rhythm, aging, etc. is improved, treated or suppressed.
- Visual impairment includes disorders such as refractive errors such as myopia, hyperopia, astigmatism and presbyopia, dysregulation, retinopathy, maculopathy, glaucoma, cataract, dry eye, conjunctivitis, and other disorders such as fatigue. It also has the effect of preventing eyestrain.
- the treatment, improvement, and prevention effects of pet diabetes in the present invention include diabetes due to an increase in blood sugar level due to lifestyle predisposition such as excessive administration of food and lack of exercise due to indoor preservation, in addition to genetic predisposition. It means that the complication is treated, ameliorated or prevented.
- the present invention is effective for both type I diabetes and type II diabetes, but more effective for type II diabetes. Insulin resistance, a characteristic of type II diabetes arising from acquired factors, is often associated with obesity, especially visceral fat accumulation, and is often accompanied by hyperlipidemia and hypertension.
- the pet food of the present invention treats, ameliorates or prevents diabetes by improving hyperglycemia, that is, reducing elevated blood glucose levels.
- the pet food of the present invention also has the effect of preventing, ameliorating, and preventing amelioration of diabetes by treating and improving nervous disorders, retinal disorders, nephropathy, and ischemic diseases, which are complications of diabetes.
- neuropathy sudden deafness, abnormalities of the eyes and face (paralysis and pain), orthostatic hypotension, diarrhea and constipation (digestive symptoms), dysuria, pain in the extremities, abnormal sensation, muscle atrophy, Treatment of gangrene Effective for 'improvement' prevention.
- it is effective against macular degeneration, glaucoma, cataract, simple retinopathy, preproliferative retinopathy and proliferative retinopathy. It is also effective in preventing ⁇ improvement '' in the treatment of cerebral infarction and myocardial infarction in ischemic diseases.
- the pet food of the present invention also has the effect of preventing, ameliorating, and preventing amelioration of diabetes by treating and improving nervous disorders, retinal disorders, nephropathy, and
- the pet food of the present invention may be in the form of a solid preparation, solid, pellet, granule, biscuit, paste, dry food, semi-dry food (for example, pet food having a water content of about 10 to 50% by weight). ) Or wet food such as canned food (eg, pet food having a water content of about 50% by weight).
- astaxanthin can be added to a pet food material and mixed at an appropriate step, or an aqueous solution of astaxanthin can be sprinkled on pet food to produce it.
- the pet food of the present invention can also be prepared by adding and mixing astaxanthin to a commercially available pet food or sprinkling it.
- human nutritional supplements it is manufactured in solid preparations such as tablets, sublingual tablets, pills, powders, powders, fine granules, granules, capsules and soft capsules that are easy to ingest. be able to.
- Raw materials that can be blended with pet food are not particularly limited as long as they can be used as pet food.
- conventional ingredients such as fish meal, fish meat, seafood, fish meal, animal meat, meat meal, meat-and-bone meal, blood meal, feather meal, silkworm chaff oil meal, skim milk powder, etc.
- Animal fats such as beef oil, pork oil, bone oil
- animal raw materials such as chicken eggs, milk, etc .
- microorganisms such as brewer's yeast and torula yeast
- corn, maize, wheat, barley, rye, oats Cereals such as wheat flour, brown rice, brown rice, soybeans, kinako, cassava
- starches such as alpha-uniform starch and starch
- soybean oil cake, dehulled soybean oil cake, rapeseed oil cake, laccase oil cake, coconut oil cake, sunflower oil cake, amaji Oil cakes such as oil cake, sesame oil cake, safari oil cake, palm kernel oil cake, kapok oil cake, etc .
- glucan feed dalten meal, starch cake
- Manufacturing lees such as honey, soy sauce lees, beer lees, beet pulp, bagasse, tofu lees, malt root, mandarin peel
- Examples of the raw materials that can be blended with the solid preparation include, in addition to the above-mentioned raw materials, carriers generally used in the field of human foods, for example, by uniformly mixing the carrier and astaxanthin. The ability to do S.
- Specific examples of the carrier include sucrose, sorbitol, and fructo.
- Sugars such as sugars, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, rapeseed oil, olive oil and soybean oil, and flavors such as strawberry flavor and peppermint.
- excipients such as ratatose, dalicose, sucrose, lactose, mannitol, corn starch, silicon dioxide, starch, sodium alginate, etc.
- Disintegrants such as magnesium stearate, talc, binders such as polybutyl alcohol, hydroxypropyl cellulose, gelatin, casein, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, saponin, lecithin Emulsifiers such as guar gum, alginic acid, carrageenan, agar, thickeners such as pectin, gum arabic, crystalline cellulose, and plasticizers such as glycerin can also be used. Tablets and soft capsules are preferred because they are easy to consume.
- the pet food may contain additives such as fortifying agents, quality improving agents, antibiotics, antibacterial agents, enzymes, fungicides, antioxidants, coloring agents, sweeteners, and flavors, if necessary. It may be.
- the content of astaxanthin in pet food is not particularly limited, and can be selected within a range that does not impair palatability.
- the content of pet food can be reduced. 0.0001 to 10% by weight, preferably 0.0005 to 5% by weight, and more preferably 0.0005 to 3% by weight, based on the total amount.
- a solid preparation in which the dose per administration or per day can be specified.
- the amount of astaxanthin in one solid preparation weighing 200 to 100 mg is free. It is 0.1 to 10 mg, preferably 0.2 to 5 mg in terms of astaxanthin.
- the dose of the pet food to the pet can be selected according to age, weight, and the like.
- 1 to 500 zgZ days per kg of body weight preferably 2300 zg / Day, more preferably about 5 to 200 xg / day.
- the administration time may be any time, and the number of administrations may be once or multiple times per day.
- Pets are animals that have been improved by humans for pets, not for food, and have many opportunities for human contact.
- Specific examples of the pet include a mouse, a rat, a guinea pig, a heron, a monkey, a dog, a cat, a hamster, a pig, a cow, a sheep, a horse, a penis, a snake, a lizard, a bird, and the like.
- Astaxanthin in the following examples is an astaxanthin oil containing an extract from Hematococcus algae manufactured by Fuji Chemical Industry Co., Ltd.
- Astaryl 50F (trade name, manufactured by Fuji Chemical Industry Co., Ltd.) in the following examples is an oil composed of a fatty acid ester of astaxanthin and 5% in terms of free astaxanthin, and a tridaliceride, [Product name, manufactured by Fuji Chemical Industry Co., Ltd.] is a powder containing 20% of Astalril 50F.
- Each of the 29 dogs (weighing 2.227 kg) was bred for 1 month by a commercial dog hood instead of a special diet. Thereafter, the same dog food and a tablet containing astaxanthin (containing lmg in terms of a free substance of astaxanthin, manufactured by Meniwan Co., Ltd.) were both given for one month. The diet was given one astaxanthin-containing tablet per meal twice a day.
- Table 1 shows the results of evaluating whether the degree of deep sleep at night, the sensitivity to external stimuli, and the sight after the one-month administration were improved compared to those before administration.
- Example 2 In the same manner as in Example 1, eight cats (body weight: 5.88 kg) were given tablets containing astaxanthin for 1 month (containing lmg in terms of a free form of astaxanthin, manufactured by Meniwan Co., Ltd.).
- Table 2 shows the results of the evaluation of whether the degree of deep sleep at night, the sensitivity to external stimuli, and the vision were improved compared to before administration.
- the odor of each sample was measured by an odor measuring device (KALMOR-II, manufactured by Kalmore). Specifically, 280mm X 200mm sealed vinyl Insert the measurement probe into the bag, measure the odor (initial value) in the plastic bag that does not contain the sample, then put the weighed lOOmg sample into the plastic bag, and after 15 minutes have passed, force the vinyl containing the sample. The odor (measured value) in the bag was measured, and the initial value of the measured value power was subtracted to obtain the odor value.
- KALMOR-II manufactured by Kalmore
- a beagle dog (a body weight of about 10 kg, 6 months old) of a diabetes mellitus model produced by administering streptozotocin (STZ) purchased from Sankyo Laboratories Co., Ltd.
- STZ streptozotocin
- One tablet 300 mg containing 0.67 mg of free astaxanthin] was mixed in the feed and administered for 4 weeks. Blood was collected at the start of the test, two weeks and four weeks after the start, blood serum was separated, and the blood glucose level was measured.
- Beagle dogs are housed in metal cages, bred under conditions of temperature 22 soil 2 ° C, humidity 55 ⁇ 10%, lighting 12 hours (7 am to 7 pm) and daily Fed with food.
- Beagle dogs were 6 months old (weight about 10 kg) and purchased from Sankyo Laboratories Co., Ltd. After the purchase, the animals were preliminarily reared for about 4 weeks, and were used after confirming that there was no abnormality in the general condition, body weight, and food consumption during that time.
- Vedanore dogs are housed in metal cages, kept at a temperature of 22 ⁇ 2 ° C, a humidity of 55 ⁇ 10%, and illuminated for 12 hours (7 am to 7 pm). Fed with food.
- Example 6 Astar reel powder
- the tablets were tableted with HT-AP18SS-II) to prepare tablet-type pet food.
- the above components were mixed and granulated using a disc pellet granulator (manufactured by Fuji Padal Co., Ltd.) to prepare 100-300 mg (size 4 mm ⁇ X about 5-10 mm). This pellet was dried at 50 ° C for 10 hours to obtain dry food.
- a disc pellet granulator manufactured by Fuji Padal Co., Ltd.
- the above components were mixed and pulverized, sieved with a sieve having an opening of lmm, and then watered so that the solid content was about 27% by weight.
- Extrusion was carried out using a cooking ethatruder (manufactured by Wenger) equipped with a round die having a diameter of 8 mm to obtain a puffed product.
- the obtained expanded product was dried at 120 ° C. for 20 minutes using a belt dryer, and then 5 parts by weight of soybean oil was sprayed on 95 parts by weight of the expanded product to obtain a dry dog food.
- Vitamin 'Mineral Mix Aster reel 50F 0.1 weight part
- each can was filled with 300g of meat along with 100g of water.
- the cans were finally retort sterilized at 120 ° C for 70 minutes.
- the can is 100mm in diameter x 120mm in height
- Each can was filled with 160g of meat along with 100g of water.
- the cans were finally retorted at 110 ° C for 80 minutes.
- Example 6 When the pet food of Examples 6 to 11 was given to a dog or a cat, they ate without any hesitation without worrying about the smell or the like. In addition, the same results as in Example 5 were obtained with respect to the excrement deodorizing effect, the sleep improving effect, the sensitivity improving effect, and the visual improving effect.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Birds (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/583,482 US20070128310A1 (en) | 2003-12-19 | 2004-12-17 | Astaxanthin-containing pet foods |
JP2005516375A JP4933097B2 (ja) | 2003-12-19 | 2004-12-17 | 糖尿病および糖尿病合併症の治療・改善方法 |
US12/962,088 US8623434B2 (en) | 2003-12-19 | 2010-12-07 | Astaxanthin-containing pet foods |
US14/100,312 US9820497B2 (en) | 2003-12-19 | 2013-12-09 | Astaxanthin-containing pet foods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003422304 | 2003-12-19 | ||
JP2003-422304 | 2003-12-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/583,482 A-371-Of-International US20070128310A1 (en) | 2003-12-19 | 2004-12-17 | Astaxanthin-containing pet foods |
US12/962,088 Continuation US8623434B2 (en) | 2003-12-19 | 2010-12-07 | Astaxanthin-containing pet foods |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005058064A1 true WO2005058064A1 (ja) | 2005-06-30 |
Family
ID=34697325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018950 WO2005058064A1 (ja) | 2003-12-19 | 2004-12-17 | アスタキサンチン配合ペット用食物 |
Country Status (3)
Country | Link |
---|---|
US (3) | US20070128310A1 (ja) |
JP (2) | JP4933097B2 (ja) |
WO (1) | WO2005058064A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099478A1 (en) * | 2004-04-16 | 2005-10-27 | Nestec S.A. | Method and compositions for reducing oxidative stress in an animal |
JP2009007346A (ja) * | 2007-05-30 | 2009-01-15 | Toyo Shinyaku:Kk | 糖尿病併発疾病予防剤 |
JP2009501527A (ja) * | 2005-07-14 | 2009-01-22 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物の生命を延長するための方法 |
JP2009011278A (ja) * | 2007-07-09 | 2009-01-22 | Hill's Pet Nutrition Inc | 糞便の体積と糞便の臭気を低減するための組成物と方法 |
JP2009298740A (ja) * | 2008-06-16 | 2009-12-24 | Fuji Chem Ind Co Ltd | 認識運動機能改善組成物 |
US8193240B2 (en) | 2004-03-17 | 2012-06-05 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
US8226973B2 (en) | 2005-11-02 | 2012-07-24 | Nestec, S. A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
US8535708B2 (en) | 2004-12-29 | 2013-09-17 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
US8592478B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition |
JP2014501536A (ja) * | 2011-01-14 | 2014-01-23 | ザ・アイムス・カンパニー | カロチノイドに関連する組成物及び方法 |
CN103766667A (zh) * | 2014-02-17 | 2014-05-07 | 韦业桂 | 一种家养蛇全价配合饲料及其制备方法 |
US8906434B2 (en) | 2007-07-09 | 2014-12-09 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
JP2020108374A (ja) * | 2018-12-28 | 2020-07-16 | ユニ・チャーム株式会社 | 総合栄養食ペットフード |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4933097B2 (ja) * | 2003-12-19 | 2012-05-16 | 株式会社メニコン | 糖尿病および糖尿病合併症の治療・改善方法 |
CA2615358C (en) * | 2005-07-15 | 2011-11-08 | Fisher Feeds Limited | Animal feed |
KR101514422B1 (ko) | 2008-05-20 | 2015-04-24 | 아주대학교산학협력단 | 해양미생물 대사체를 유효성분으로 포함하는 당뇨병 예방또는 치료용 조성물 |
US20090297492A1 (en) * | 2008-05-30 | 2009-12-03 | Yamaha Hatsudoki Kabushiki Kaisha | Method for Improving Cognitive Performance |
MX2013006353A (es) * | 2010-12-07 | 2013-08-26 | Nestec Sa | Metodos y composiciones utiles para promover el sueño en animales. |
AU2013230671B2 (en) * | 2012-03-05 | 2016-12-15 | Gratuk Technologies Pty Ltd | Dietary supplement |
US20130295075A1 (en) * | 2012-05-03 | 2013-11-07 | Orasis | Compositions and methods of treating glaucoma |
EP3040069A4 (en) * | 2013-06-27 | 2017-04-12 | The Doshisha | Intestinal flora improving composition containing astaxanthin |
JP6064140B2 (ja) * | 2015-06-05 | 2017-01-25 | Fsk三昭株式会社 | 飼料の生産方法 |
EP3231421A1 (en) * | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
JP2017218424A (ja) | 2016-06-08 | 2017-12-14 | アスタリール株式会社 | 認知機能向上のための運動療法において使用するための、カロテノイドを含む認知機能向上組成物 |
US11260099B2 (en) * | 2016-12-16 | 2022-03-01 | Hills Pet Nutrition, Inc. | Pet food compositions |
EP3632422A4 (en) * | 2017-05-23 | 2021-03-10 | Nippon Suisan Kaisha, Ltd. | COMPOSITION FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION |
WO2020196557A1 (ja) * | 2019-03-28 | 2020-10-01 | 富士フイルム株式会社 | 乳化組成物及びこれを含む飲料 |
CN112515049A (zh) * | 2020-11-09 | 2021-03-19 | 南京未来宠物产业研究院有限公司 | 一种虾青素在制备功能性宠物食品中的应用 |
CN114747686A (zh) * | 2022-03-14 | 2022-07-15 | 青岛彬利宠物用品有限公司 | 一种含天然虾青素的宠物猫粮 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000507821A (ja) * | 1996-03-27 | 2000-06-27 | アスタカロテーヌ、アクチボラグ | 育種哺乳動物および生産哺乳動物の生産を増加させる因子 |
WO2003013268A1 (en) * | 2001-08-03 | 2003-02-20 | Mars Uk Limited | Foodstuff |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1204666A (en) | 1982-03-08 | 1986-05-20 | Richard J. Wurtman | Method for improving sleep |
JP2865779B2 (ja) | 1990-03-15 | 1999-03-08 | タマ生化学株式会社 | 家畜動物用飼料添加剤 |
JP2623055B2 (ja) | 1991-10-11 | 1997-06-25 | 株式会社東洋発酵 | 発酵健康飼料 |
JP3266943B2 (ja) | 1992-09-16 | 2002-03-18 | 住友ベークライト株式会社 | 医療用酸素供給装置 |
US5654325A (en) | 1993-11-18 | 1997-08-05 | Eli Lilly And Company | Melatonin derivatives for use in treating sleep disorders |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
US6022867A (en) * | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
JPH10175866A (ja) * | 1996-12-18 | 1998-06-30 | Showa Denko Kk | 動物用ストレス反応緩和剤及びストレス反応の緩和方法 |
US5937790A (en) * | 1996-12-18 | 1999-08-17 | Showa Denko Kabushiki Kaisha | Anti-stress agent for animals and a method of reducing stress in animals |
SE522246C2 (sv) | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
JPH10276721A (ja) | 1997-04-11 | 1998-10-20 | Suntory Ltd | アスタキサンチン含有飲食物 |
SE524337C2 (sv) * | 1998-10-16 | 2004-07-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk behandling av matsmältningsbesvär |
US6086886A (en) * | 1998-10-22 | 2000-07-11 | Jarrow Formulas, Inc. | Composition for promoting intestinal health |
EP1050303A3 (en) | 1999-04-27 | 2003-01-15 | Pfizer Products Inc. | Methods and compositions for treating age-related behavioral disorders in companion animals |
SE9903619D0 (sv) * | 1999-10-07 | 1999-10-07 | Astacarotene Ab | Use and method of treatment |
JP2001258480A (ja) | 2000-03-17 | 2001-09-25 | Ota Isan:Kk | 動物糞尿臭消臭用飼料 |
US20030104090A1 (en) * | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
ES2312430T3 (es) * | 2000-05-16 | 2009-03-01 | Suntory Limited | Composicion normalizadora del ritmo circadiano. |
JP2002114690A (ja) | 2000-10-12 | 2002-04-16 | Taiyo Kagaku Co Ltd | 排便消臭剤 |
JP3778509B2 (ja) | 2001-05-24 | 2006-05-24 | 富士化学工業株式会社 | 眼の調節機能障害改善剤 |
US20030124230A1 (en) * | 2001-06-01 | 2003-07-03 | Jan Zielinski | Methods and products for bad breath |
US20030170328A1 (en) * | 2002-01-16 | 2003-09-11 | David Haines | Anti-inflammatory formulations |
US20040151761A1 (en) * | 2003-02-05 | 2004-08-05 | The Procter & Gamble Company | Methods and compositions utilizing astaxanthin |
US20040234579A1 (en) * | 2003-05-22 | 2004-11-25 | Mark D. Finke, Inc. | Dietary supplements and methods of preparing and administering dietary supplements |
JP4933097B2 (ja) * | 2003-12-19 | 2012-05-16 | 株式会社メニコン | 糖尿病および糖尿病合併症の治療・改善方法 |
CN101095698B (zh) * | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途 |
JP5192087B2 (ja) | 2009-12-01 | 2013-05-08 | パナソニック株式会社 | 画像処理装置及び画像処理方法 |
-
2004
- 2004-12-17 JP JP2005516375A patent/JP4933097B2/ja active Active
- 2004-12-17 WO PCT/JP2004/018950 patent/WO2005058064A1/ja active Application Filing
- 2004-12-17 US US10/583,482 patent/US20070128310A1/en not_active Abandoned
-
2010
- 2010-12-07 US US12/962,088 patent/US8623434B2/en active Active
-
2011
- 2011-05-02 JP JP2011102851A patent/JP2011167203A/ja active Pending
-
2013
- 2013-12-09 US US14/100,312 patent/US9820497B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000507821A (ja) * | 1996-03-27 | 2000-06-27 | アスタカロテーヌ、アクチボラグ | 育種哺乳動物および生産哺乳動物の生産を増加させる因子 |
WO2003013268A1 (en) * | 2001-08-03 | 2003-02-20 | Mars Uk Limited | Foodstuff |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592478B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition |
US8193240B2 (en) | 2004-03-17 | 2012-06-05 | Nestec S.A. | Compositions and methods for reducing or preventing obesity |
US8034373B2 (en) | 2004-04-16 | 2011-10-11 | Nestec S. A. | Methods and compositions for reducing oxidative stress in an animal |
WO2005099479A1 (en) * | 2004-04-16 | 2005-10-27 | Nestec S.A. | Methods and compositions for reducing oxidative stress in an animlal |
JP2007532121A (ja) * | 2004-04-16 | 2007-11-15 | ネステク ソシエテ アノニム | 動物における酸化ストレスを低減する方法および組成物 |
WO2005099478A1 (en) * | 2004-04-16 | 2005-10-27 | Nestec S.A. | Method and compositions for reducing oxidative stress in an animal |
US8535708B2 (en) | 2004-12-29 | 2013-09-17 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
JP2009501527A (ja) * | 2005-07-14 | 2009-01-22 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 動物の生命を延長するための方法 |
US8226973B2 (en) | 2005-11-02 | 2012-07-24 | Nestec, S. A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
US9427002B2 (en) | 2005-11-02 | 2016-08-30 | Nestec S.A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
JP2009007346A (ja) * | 2007-05-30 | 2009-01-15 | Toyo Shinyaku:Kk | 糖尿病併発疾病予防剤 |
JP2009011278A (ja) * | 2007-07-09 | 2009-01-22 | Hill's Pet Nutrition Inc | 糞便の体積と糞便の臭気を低減するための組成物と方法 |
US8906434B2 (en) | 2007-07-09 | 2014-12-09 | Hill's Pet Nutrition, Inc. | Compositions and methods for reducing stool volume and stool odor |
JP2009298740A (ja) * | 2008-06-16 | 2009-12-24 | Fuji Chem Ind Co Ltd | 認識運動機能改善組成物 |
JP2014501536A (ja) * | 2011-01-14 | 2014-01-23 | ザ・アイムス・カンパニー | カロチノイドに関連する組成物及び方法 |
CN103766667A (zh) * | 2014-02-17 | 2014-05-07 | 韦业桂 | 一种家养蛇全价配合饲料及其制备方法 |
CN103766667B (zh) * | 2014-02-17 | 2015-06-03 | 韦业桂 | 一种家养蛇全价配合饲料及其制备方法 |
JP2020108374A (ja) * | 2018-12-28 | 2020-07-16 | ユニ・チャーム株式会社 | 総合栄養食ペットフード |
JP7423306B2 (ja) | 2018-12-28 | 2024-01-29 | ユニ・チャーム株式会社 | 総合栄養食ペットフード |
Also Published As
Publication number | Publication date |
---|---|
US9820497B2 (en) | 2017-11-21 |
JP2011167203A (ja) | 2011-09-01 |
US20140094524A1 (en) | 2014-04-03 |
US20110077307A1 (en) | 2011-03-31 |
US8623434B2 (en) | 2014-01-07 |
JPWO2005058064A1 (ja) | 2007-07-12 |
JP4933097B2 (ja) | 2012-05-16 |
US20070128310A1 (en) | 2007-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4933097B2 (ja) | 糖尿病および糖尿病合併症の治療・改善方法 | |
US20100086638A1 (en) | Feed formulations containing docosahexaenoic acid | |
US20110251153A1 (en) | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | |
KR102409377B1 (ko) | 반려동물용 눈 건조 개선 및 눈물 착색 예방을 위한 조성물 | |
KR20190027434A (ko) | 기호성 및 보존안정성이 개선된 반려동물용 사료의 제조방법 | |
JP2005535314A (ja) | 解毒及び癌予防用の栄養組成物 | |
CN103493983A (zh) | 一种提高毛皮动物毛皮质量的饲料添加剂及其制作方法 | |
US20060189566A1 (en) | Muscle building agent and preventive or remedy for muscle weakening | |
CN106720956A (zh) | 一种鲤鱼饲料 | |
KR102035261B1 (ko) | 사료 첨가제 조성물 | |
Heuser | Feeding Poultry: The Classic Guide to Poultry Nutrition for Chickens, Turkeys, Ducks, Geese, Gamebirds, and Pigeons | |
KR100847354B1 (ko) | 잣나무잎을 이용한 동물사육방법 및 이를 이용하여 생산된기능성 산물 | |
JP2006304755A (ja) | ペット用食物 | |
KR102457595B1 (ko) | 항균성을 높인 반려동물용 사료 및 그 제조방법 | |
KR102147761B1 (ko) | 메추리 품종육종 방법 | |
WO2007114437A1 (ja) | セサミン類含有動物用飲食物 | |
KR20190054813A (ko) | 갈색거저리를 포함하는 식이 알러지 저감용 사료조성물 및 이의 용도 | |
CN112515049A (zh) | 一种虾青素在制备功能性宠物食品中的应用 | |
KR102407619B1 (ko) | 고양이 헤어볼 배출 개선용 조성물 | |
CN106819576A (zh) | 有益微生物无抗生物饲料添加剂及其制备方法和应用 | |
KR101833491B1 (ko) | 자이언트 켈프를 포함하는 기능성 사료 조성물 및 이를 이용한 가축의 사육방법 | |
DE202023000357U1 (de) | Katzenfutter mit Ginseng-Extrakt | |
WO2024076752A1 (en) | Food compositions for companion animals | |
KR20240048595A (ko) | 항균성을 높인 반려동물용 사료 및 그 제조방법 | |
CN117678681A (zh) | 一种具有化毛功能宠物冻干牛蛙零食及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516375 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007128310 Country of ref document: US Ref document number: 10583482 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10583482 Country of ref document: US |